Skip to main content

Prior Authorization Policies for Pediatric ADHD Medication Prescriptions

Loading...

About this dataset:

According to the Centers for Disease Control and Prevention, more than 6.4 million US children aged 4-17 years have had attention-deficit/hyperactivity disorder (ADHD) diagnosed. The percentage of US children diagnosed with ADHD has increased by 3 to 5 percent per year since the 1990s. Relatedly, the percentage of children in this age group taking ADHD medication also has increased by about 7 percent per year from 2007-2008 to 2011-2012. Some state Medicaid programs have implemented policies to manage the use of ADHD medications and guide physicians toward best practices for ADHD treatment in children. These policies include prescription medication prior authorization requirements that restrict approvals to patients above a certain age, or require additional provider involvement before approval for payment is granted.

This map examines features of state Medicaid prior authorization policies that pertain to pediatric ADHD medication treatment, including applicable ages, medication types, and criteria for approval.

Cited By

Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder in Young Children, United States, 2015

Public Health Reports
Medicaid Prior Authorization Policies for Medication Treatment of Attention-Deficit/Hyperactivity Disorder in Young Children, United States, 2015
Rachel L. Hulkower, Meghan Kelley, Lindsay K. Cloud, & Susanna N. Visser
Off
Hulkower

Dataset Created by
Policy Surveillance Program and CDC Staff

Dataset Maintained by
Policy Surveillance Program Staff

Dataset Valid From
November 1, 2015

Dataset Updated Through
November 1, 2015

Total Jurisdictions Covered
51